TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06969430: A Phase 1/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Sponsor: Debiopharm International SA · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 154 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06969430 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06969430 Rescue Dossier →